← Eichor
Study identifier: NCT07536100 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

VENEZE Peptide Factor Hair Serum Compared With Topical 2% Minoxidil for Androgenetic Alopecia

Condition: Androgenetic Alopecia (AGA)  ·  Sponsor: Institute of Dermatology, Thailand

PhaseNA
Planned participants80
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study aims to evaluate the effectiveness and tolerability of a peptide-based hair serum compared with topical minoxidil in patients with androgenetic alopecia. Participants will be randomly assigned, in a double-blind manner, to receive either the peptide hair serum or topical minoxidil. The primary objective is to assess improvement in hair growth over the study period, including changes in hair density and hair thickness. Secondary outcomes will include safety and tolerability assessments. The findings of this study may provide evidence supporting an alternative treatment option for patients with androgenetic alopecia.

This description comes directly from the study's public registry record.

Talk to the study team

Chinmanat Lekhavat, MD, PhD  ·  66023545222  ·  chinmanat@inderm.org

Suchanaree Laitrakul, MD  ·  66023545222

Always discuss trial participation with your own doctor first.

Locations (2)

Institute of dermatologyBangkok, Bangkok, ThailandRecruiting
Institute of DermatologyBangkok, ThailandRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07536100